Advanced search
Publication Cover
Modern Rheumatology Volume 19, 2009 - Issue 4
Journal homepage
12
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Sjögren’s syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment

Koichiro KomaiDivision of Rheumatology, Department of Medicine and Biophysics, Kobe University Graduate School of Medicine and Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan
,
Kazuko ShiozawaRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Yasushi TanakaRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Ryosuke YoshiharaRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Chihiro TanakaRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan;Division of Rheumatology, Department of Medicine and Biophysics, Kobe University Graduate School of Medicine and Health Sciences, 7-5 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
,
Hideo SakaiRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Takashi YamaneRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Miki MurataRheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
,
Ken TsumiyamaDivision of Rheumatology, Department of Medicine and Biophysics, Kobe University Graduate School of Medicine and Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan
,
Akira HashiramotoDivision of Rheumatology, Department of Medicine and Biophysics, Kobe University Graduate School of Medicine and Health Sciences, 7-5 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan;The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan
&
Shunichi ShiozawaThe Center for Rheumatic Diseases, Kobe University Hospital, Kobe, JapanCorrespondence[email protected]
 show all
Pages 416-419 | Received 25 Feb 2009, Accepted 09 Apr 2009, Published online: 02 Jan 2014

References

  • Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252–61.
  • Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome. Adv Exp Med Biol. 2002;506(Pt B):1107–16.
  • Iwabuchi Y, Masuhara T. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat sali-vary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. Gen Pharmacol. 1994;25(1): 123–9.
  • Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293–300.
  • Miyawaki S. Revised Japan criteria for Sjögren syndrome. Ryumachi. 2000;40(1):48–53.
  • Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28(10):1128–32.
  • Shiozawa S, Cummins JM, Fox PC. Opening the flood gates: interferon-alpha treatment for Sjögren's syndrome. BioDrugs. 2000;13(5):305–11.
  • Dömer T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007;3(5):953–9.
  • Manganelli P, Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritis Rheum. 2003;33(1):49–65.
  • Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher 0, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunol. 1996;104(3):454–9.
  • Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum. 2006; 54(4):1165–73.
  • Ogawa N, Dang H, Lazaridis K, McGuff HS, Aufdemorte TB, Talal N. Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjogren's syndrome). J Interferon Cytokine Res. 1995;15(9):759–67.
  • Berra A, Sterin-Borda L, Bacman S, Borda E. Role of salivary IgA in the pathogenesis of Sjögren syndrome. Clin Immunol. 2002;104(1):49–57.
  • Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res. 1998;18(4):255–62.
  • Nakabayashi T, Letterio JJ, Geiser AG, Kong L, Ogawa N, Zhao W, et al. Up-regulation of cytokine mRNA, adhesion molecule proteins, and MHC class II proteins in salivary glands of TGF-betal knockout mice: MHC class II is a factor in the pathogenesis of TGF-betal knockout mice. J Immunol. 1997;158(11):5527–35.
  • Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006;54(7):2300–5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.